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Honey is known not only as a natural food but also as complementary medicine. According to 
the controversial evidence about the effects of honey on blood lipids, this meta-analysis was 
performed to investigate the potential effects of honey on lipid profiles. Relevant studies were 
identified by searching PubMed, Web of Science (WOS), Scopus, EMBASE, and Cochrane 
databases. All human controlled clinical trials (either with a parallel or a crossover design) 
published in English that reported changes in serum lipid markers (Total Cholesterol (TC), 
Triglyceride (TG), Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein 
Cholesterol (HDL-C), and LDL-C/HDL-C ratio) following honey consumption were considered. 
Standardized Mean Differences (SMDs) and their respective 95% Confidence Intervals (CIs) 
were calculated to assess the changes in lipid profiles following honey consumption by random 
effects model. Statistical heterogeneity, sensitivity analysis, publication bias, and quality of the 
included studies were assessed, as well. The meta-analysis of 23 trials showed that honey had no 
significant effects on TC, TG, LDL-C, HDL-C, and LDL-C/HDL-C ratio. Significant 
heterogeneity was seen among the studies for all the studied factors (I2
 
index > 50%). Subgroup 
analysis based on the lipid profile status, types of honey, and intervention duration revealed no 
significant effect on TC, TG, LDL-C, and HDL-C. Quality of the evidences varied form very 
low to moderate according to various parameters. In conclusion, honey consumption did not 
affect serum lipid profiles (TC, TG, LDL-C, HDL-C, and LDL-C/HDL-C ratio). 
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1. Introduction  
Cardiovascular Diseases (CVDs) are the main cause of morbidity and mortality, accounting for 
31% of all global deaths. Lipid abnormalities are the most important contributors to CVDs that 
include increased concentrations of Total Cholesterol (TC), Low Density Lipoprotein 
Cholesterol (LDL-C), and Triglycerides (TG) as well as decreased concentrations of High 
Density Lipoprotein Cholesterol (HDL-C) and its combinations 
(1)
.  
Diet modification remains the main strategy for CVD management and lipid profile control. The 
important role of a healthy diet and natural food in promoting health, improving general well-
being, and reducing the risk of some chronic diseases has been widely accepted 
(2)
. Functional 
foods, known as nutraceuticals, therapeutic foods, or super foods, have a targeted effect on the 
function of organisms and can promote physiological and/or psychological health 
(3)
. Bee 




Honey is a natural food containing numerous beneficial compounds, such as proteins, amino 
acids, vitamins, minerals, and phytochemicals. Caffeic and p-Coumaric acids, Catechin, 
Quercetin, Chrysin, and Kaempferol are the common phenolic compounds and flavonoids in 
honey 
(5)
. Honey has been considered a complementary medicine since the earliest times 
(6)
. 
Recent studies have highlighted that honey has numerous medical outcomes with its anti-obesity, 
anti-hypertensive, and anti-diabetic properties, positive-cardiovascular effects, and 
hypolipidemic activities 
(7; 8; 9; 10; 11)
. These properties of honey are mainly related to its phenolic 
compounds, which define its unique biological activities, flavor, and aroma 
(12)
.  
Despite these potential health benefits, 95% of honey dry matter contains carbohydrates, 
especially fructose and glucose 
(5)
. Fructose as a dietary sugar has been suggested to be a main 
factor that increases lipid synthesis. Therefore, chronic high fructose consumption might 
reinforce the capacity of lipid synthesis and increase plasma lipid concentration that promote 
CVDs 
(13)
. Hence, there is controversy about the effects of honey on lipid profiles.  
The latest meta-analysis on 10 trials revealed the beneficial effects of honey on lipid profiles, 
including LDL-C, TG, and HDL-C 
(14)
. However, some recent studies have not confirmed the 
lipid-lowering properties of honey 
(15; 16)
. Despite the numerous potential biological activities 
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profiles are still a matter of debate. The current study updated the previous meta-analysis on the 
effect of honey on lipid profiles 
(14)
, and included several more recent trials (23 studies) to draw a 
better conclusion in this regard. 
2. Methods 
2.1 Search Strategy 
Two investigators independently conducted literature searches in five databases (PubMed, Web 
of Science (WOS), Cochrane, Scopus, and EMBASE) until February 2021 to find controlled 
clinical trials. The following keywords were used: ((honey*)) AND ((cholesterol*) OR (LDL*) 
OR (TC) OR (HDL*) OR (triglyceride*) OR (TG) OR (lipoprotein*) OR ("lipid profile") OR 
(Lipid*) OR ("cardiovascular disease") OR ("heart disease") OR (hypercholesterolemia*)) NOT 
((rat) OR (mouse) OR (vitro*) OR (animal*)). Titles and abstracts were screened by two 
independent investigators (Z.GH and Z.S) and full-texts were assessed for eligibility.  
2.2 Eligibility criteria 
The inclusion criteria for the studies were (1) being published in English and (2) being a 
controlled clinical trial (either parallel or crossover design). However, (1) non-human studies 
(animal, in-vitro, and in-vivo studies), (2) cross-sectional studies, (3) reviews, (4) grey literature 
(book chapters, abstracts in conferences, editorials, letters, and seminars), (5) studies without any 
control groups, and (6) studies lacking information for extracting mean and SD (or SE) were 
excluded. No restriction was considered on the type of controlled clinical trial (crossover or 
parallel; randomized or non-randomized), type of honey, dose of honey, intervention duration, 
and participants (age, sex, Body Mass Index (BMI), and health condition).  
In this meta-analysis, all lipid profiles; i.e., TC, TG, LDL-C, HDL-C, and LDL-C/HDL-C ratio, 
were considered primary outcomes. 
2.3 Methodological quality appraisal 
For assessing the quality of Randomized Clinical Trials (RCTs) based on the criteria outlined in 
the Cochrane Handbook for Systematic Reviews of Interventions, the Cochrane Collaboration 
Risk of Bias Tool (CCRT) was used 
(17)
. The following domains were assessed: random 
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of outcome assessment, incomplete outcome data, selective outcome reporting, and other sources 
of bias. Finally, the potential sources of bias were classified into “low”, “high”, and “unclear” 
categories.  
Quality assessment of non-randomized studies was performed by using the ROBINS-I tool 
(18)
. 
The following domains were assessed: bias due to confounding, bias in selection of participants, 
bias in classification of interventions, bias due to deviations from the intended interventions, bias 
due to missing data, bias in measurement of the outcome, and bias in selection of the reported 
results. Finally, the potential sources of bias were classified into “low”, “moderate”, “serious”, 
and “critical” categories. 
2.4 GRADE profile 
Overall assessment of evidences was done using the Grading of Recommendations Assessment, 
Development, and Evaluation (GRADE) approach 
(19)
. In this context, six criteria were 
considered to evaluate the quality of the evidences, including risk of bias, inconsistency, 
indirectness, imprecision, publication bias, and effect size. 
2.5 Statistical analysis 
The mean difference and SD of the changes between baseline and post-intervention were used 
for control and intervention groups (for crossover studies: different conditions of control and 
intervention) to assess the pooled final effects. To calculate SD in cases where it was expressed 
as SE or upper and lower limits, the following formula was employed: SD = √n × SE or √n × 
(upper limit – lower limit) / 3.92. The differences in the mean values at baseline and at the end of 
the study were used for the time that the effect size was not reported. The mean and SD were 
elicited from the reviewed studies and the data were report differently. Hozo et al. used this 
method as follows: SD=square root [(SD pre-treatment) 2 + (SD post-treatment) 2 – (2R × SD 
pre-treatment × SD post-treatment)] 
(20)
. One mmol/l was considered equivalent to 38.66976 
mg/dL for TC, LDL-C, and HDL-C and to 88.57396 mg/dL for TG. The random effects model 
(DerSimonian and Laird method) was used in order to estimate the effect size and the results 
were reported across Weighted Mean Difference (WMD) and 95% Confidence Intervals 
(CI). Statistical heterogeneity was examined with the I
2
 test by using random inverse-variance 
heterogeneity. Moderate heterogeneity was defined as I
2
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done to determine the sources of heterogeneity based on the lipid profile status of the participants 
at baseline [dyslipidemia status (at least one of these: mean TC>200 mg/dL, TG>200 mg/dL, 
LDL-C>130 mg/dL, or HDL-C<40mg/dL) and normal lipid profile status], and intervention 
duration [≤8 weeks, >8 weeks, and acute studies]. The publication bias was evaluated by 
assessing funnel plots and Egger’s test. Sensitivity analysis was also performed for all lipidemic 
indices. STATA, V13.0 was used for meta-analysis, and p<0.05 was considered significant. 
3. Results 
3.1 Search results 
The process of selection of 23 trials for the meta-analysis has been presented in Figure 1. 
Accordingly, five databases were searched and 1188 references were identified, 1156 ones of 
which were excluded due to their titles and abstracts (443 duplicates and 713 irrelevant studies). 
For the 32 studies included up to this step, full-texts were assessed for eligibility and nine studies 
were excluded due to the following reasons: 1) not including a control group and 2) insufficient 
information. Finally, 23 trials and 1109 subjects were entered into the meta-analysis (Figure 1).  
3.2 Characteristics of the included studies 
The characteristics of the included studies have been shown in Table 1. The publication date for 
these studies ranged from 1988 to 2020. The studies were done in Iran (n=6) 




, Malaysia (n=3) 
(27; 28; 29)
, Indonesia (n=2) 
(30; 31)





, New Zealand (n=1) 
(35)
, Egypt (n=1) 
(36)
, Germany (n=1) 
(37)





, Saudi Arabia (n=1) 
(40)
, and Greece (n=1) 
(41)
. The studies were performed on healthy, 
overweight, obese, glucose-intolerant, and hyperlipidemic participants, diabetics (type 2, type 1, 
and nephropathy diabetics), postmenopausal women, individuals undergoing elective surgery, 
and asymptomatic treatment-naïve HIV-infected patients. The mean ages of the participants 
ranged from 11 to 62 years. Among the included trials, five used a crossover design, while 18 
followed a controlled parallel design. One study was only conducted on females 
(30)
, three were 
only performed on males 
(22; 32; 33)
, and the remaining 19 included both sexes. BMI ranged from 
21-36 kg/m
2
, while this measure was not mentioned in seven studies 
(24; 30; 32; 33; 34; 39; 40)
. 
Moreover, various types of honey, such as natural, native, and formulated, as well as honey 
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months. TC, TG, LDL-C, HDL-C, LDL/HDL-C ratio, and Very Low Density Lipoprotein 
Cholesterol (VLDL-C) were measured in 20, 21, 19, 18, 2, and 1 out of the 23 trials, 
respectively. Details of the methodological quality assessment have been presented in Tables 3.a 
and 3.b.  
3.3 Risk of bias assessment  
As shown in Table 3.a, except for four studies 
(27; 30; 31; 38)
 that did not perform randomization and 
their quality assessment was done separately according to the ROBINS-I tool (Table 3.b), 
randomization was done in the rest of studies and, consequently, they were regarded as having a 
low risk of bias. Concealment was mentioned in one study 
(21)
, which was regarded as having a 
low risk of bias in allocation concealment. However, six studies 
(22; 26; 33; 34; 37; 40)
 had an unclear 
risk of bias and the other 13 studies had a high risk of bias. Furthermore, five studies 
(21; 22; 26; 37; 
40)
 were double-blind RCTs and were considered as having a low risk of bias for the blinding of 
the participants and personnel. Four trials 
(21; 22; 35; 40)
 provided a clear explanation for the 
blinding of outcome assessment, and other issues were considered as low risk. In this regard, one 
study had an unclear risk 
(37)
 and the rest had a high risk of bias. Four studies 
(16; 27; 32; 34)
 were not 
clear in providing complete outcome data, and one 
(26)
 was found to have a high risk. Moreover, 
five studies 
(15; 16; 21; 28; 36)
 had a low risk of bias in selective reporting, while the remaining 14 had 
an unclear risk of bias. Two studies 
(28; 34)
 had other sources of bias. Except for four studies 
(21; 22; 
37; 40)
 that had an unclear risk of bias, the other 15 trials were found to have a high risk of bias for 
at least one of the six main domains. Therefore, these studies had a “high” quality. 
As shown in Table 3.b, in case of bias due to confounding and bias in selection of the reported 
results, two of the studies had a moderate risk of bias 
(30; 38)
 and two others had a low risk of bias 
(27; 31)
. Considering bias in selection of participants, bias in classification of interventions, and 
bias due to deviations from the intended interventions, the information given for all four studies 
was insufficient. In contrast, bias in measurement of the outcome was serious for all four studies. 
In case of bias due to missing data, except for one study 
(38)
 with a low risk of bias, the 
information for the rest of studies was not sufficient. All four studies seemed to be at a serious 
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3.4 Quality of evidence 
GRADE results have been presented in Table 4. The quality of evidence was found to be 
moderate for serum TC, TG, and HDL-C concentrations. However, GRADE quality was low for 
serum LDL-C concentration and very low for serum LDL/HDL-C ratio due to the limited sample 
size, considerable statistical heterogeneity, and serious risk of bias. 
3.5 Main documents 
3.5.1 Effect of honey on TC  
As stated above, 20 out of the 22 trials assessed the effect of honey consumption on TC level. 
The results revealed that honey consumption had no significant effects on TC [SMD: -0.15 
mg/dL; 95% CI: -0.38, 0.08; P=0.194]. In other words, honey lowered TC by 0.15 mg/dL, which 
was not statistically significant (Figure 2). There was a significant moderate heterogeneity 
among the studies (I
2
=69.9%; P=0.000). Thus, the studies were stratified to find the possible 
sources of heterogeneity. The results showed that baseline lipid profile status was the possible 
source of heterogeneity. Subgroup analysis according to the participants’ lipid profile status at 
baseline showed no significant effects of honey on TC concentration among the participants with 
dyslipidemia and normal lipid profiles (Table 2). 
3.5.2 Effect of honey on TG 
The effect of honey consumption on TG was assessed in 21 trials. The results indicated that 
honey consumption had no significant effects on TG [SMD: -0.0 mg/dL; 95% CI: -0.23, 0.23; 
P=1.00], with significant moderate heterogeneity among the trials (I
2
=73.7%; P=0.000) (Figure 
3). Subgroup analysis based on lipid profile status and intervention duration revealed that honey 
had no significant impacts on TG concentration (Table 2). 
3.5.3 Effect of honey on LDL-C 
The effect of honey on LDL-C concentration was reported in 19 trials. The results showed that 
honey had no significant effects on LDL-C concentration [SMD: -0.12 mg/dL; 95% CI: -0.33, 
0.09; P=0.274; I
2
=64.6%, P=0.000] (Figure 4). The results of subgroup analysis regarding the 
participants’ lipid profile status and intervention duration demonstrated that honey had no 
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3.5.4 Effect of honey on HDL-C 
The effect of honey on HDL-C concentration was examined in 18 trials. The results indicated 
that honey had no significant effects on HDL-C concentration [SMD: 0.04 mg/dL; 95% CI: -
0.19, 0.28; P=0.718; I
2
=70.9%, P=0.000] (Figure 5). Intervention duration was identified as the 
possible source of heterogeneity. Subgroup analysis according to the participants’ lipid profile 
status and intervention duration showed that honey consumption had no significant effects on 
HDL-C concentration (Table 2). 
3.5.5 Effect of honey on LDL/HDL-C, Total-/HDL-C, and VLDL-C 
The effect of honey on the LDL-C/HDL-C ratio was evaluated in two trials. According to the 
findings, honey lowered the LDL-C/HDL-C ratio by 0.26 mg/dL, which was not statistically 
significant [SMD: -0.17 mg/ dL; 95% CI: -1.296, 0.955; P=0.767, I
2
=88.1%, P=0.004] (Figure 
6). Moreover, Arani et al. 
(21)
 examined the effect of consumption of probiotic honey for 12 
weeks on Total-/HDL-c and VLDL-C among nephropathy diabetics. The results revealed a 
significant decrease in the Total-/HDL-C ratio (P=0.04), but no significant difference in VLDL-
C (P>0.05).  
3.5.6 Publication bias 
Based on the funnel plot and Egger’s test, publication bias was found in the trials on LDL-C 
(P=0.020), but not in those on TC (P=0.316), TG (P=0.350), HDL-C (P=0.674), and LDL-
C/HDL-C ratio (Figure 7). 
3.5.7 Sensitivity analysis  
Sensitivity analysis was conducted for the meta-analysis of the effect of honey on TC, TG, LDL-
C, HDL-C, and LDL-C/HDL-C ratio. In the sensitivity analysis of each outcome, the results 
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To the best of our knowledge, this meta-analysis was an update of a previous meta-analysis to 
review the available literature and current control trials about the effects of honey consumption 
on lipid profiles in adults. In other words, this study updated the results of a previous meta-
analysis regarding the effects of honey on blood lipids. In that study, 10 eligible trials on the 
effects of honey on blood lipids were assessed and the final results were reported with low 
certainty. The results revealed the positive impact of honey consumption on some blood lipids, 
including LDL-C, TG, and HDL-C 
(14)
. It should be noted that the previous research was 
conducted on 10 studies. The current meta-analysis, however, was conducted on 23 studies on 
the effects of honey on blood lipids and different results were found. It was reported in the 
current study that honey consumption could not affect blood lipids significantly. Hence, the 
results of the previous meta-analysis by Tul-Noor et al. 
(14)
 should be interpreted with caution. In 
addition, more reviews or RCTs are needed to draw a better conclusion about the effects of 
honey on blood lipids.  
The results of the current study showed that honey did not have any significant effects on TC, 
TG, HDL-C, LDL-C, and VLDL-C concentrations as well as on the LDL-C/HDL-C ratio. 
However, there was a high heterogeneity among the studies about the effects of honey on blood 
lipids, which was decreased by sub-group analysis and taking into account the characteristics of 
the included studies, such as duration and baseline lipid profiles. In the same line, Wahab et al. 
disclosed that honey had no significant effects on lipid profiles amongst postmenopausal women 
(42)
. In another study performed on healthy adults, it was hypothesized that compared to sucrose, 
honey consumption did not negatively affect blood lipids, including HDL-C and LDL-C. They 
believed that honey consumption could reduce energy and carbohydrate intake without 
negatively affecting blood lipids compared to sucrose among healthy participants 
(16)
. In another 
study, eight weeks of honey consumption led to a reduction in LDL-C, TC, and TG 
concentrations and LDL-C/HDL-C ratio in diabetic patients, which was on the contrary to the 
results of the current meta-analysis 
(24)
. The difference might be pertinent to the study population. 
Al-waili et al. attributed the hypolipidemic effects of natural honey to its special ingredients 
(39)
. 
The difference between the aforementioned study 
(39)
 and the current one might result from the 
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or natural honey since this was not mentioned in all the included studies. On the other hand, the 
fructose content of honey (especially artificial honey) could increase blood TG level due to its 
effect on postprandial lipid profiles 
(43)
. However, the present study results revealed no 
significant increase in TG concentration after honey consumption, which could be justified by 
the antioxidant content of honey, such as vitamin C, beta-carotene, and glutathione reductase 
(44)
. 
In contrast, niacin is present in honey and can inhibit lipolysis in adipose tissue, eventually 
reducing hepatic TG synthesis 
(33)
. That is why no increase was detected in TG concentration 
after honey consumption in spite of its fructose content. Moreover, regarding the sub-group 
analysis, the results of lipid profiles did not change considering baseline lipid concentrations 
following honey consumption.  
Obviously, fructose in various foods can affect serum TG level by bypassing 
phosphofructokinase regulatory step in glycolysis pathway, which can cause 
hypertriglyceridemia 
(45)
. Nevertheless, the effect of honey fructose on increasing the TG 
concentration has not been reported due to the active and beneficial ingredients of honey, such as 
antioxidants, that can positively affect the serum TG concentration 
(36)
, but it might reduce the 
hypolipidemic effects of honey on blood lipids as no change was reported in blood lipids 
following honey consumption in the present review. Flavonoids are among these important 
constituents showing antioxidant and hypolipidemic effects 
(36; 46)
. On the other hand, the effects 
of honey fructose on serum TG level depend on a variety of factors. For example, fructose or 
glucose consumption has been found to be associated with increased TG levels in hypercaloric 
diets, but not in weight maintenance diets 
(47; 48)
. Furthermore, when fructose in the diet was 
replaced with a large amount of starch, it could induce hypertrigyceridemia even in controlled 
diets 
(49; 50)
. Hence, the whole diet or other constituents of a diet, especially the calorie or starch 
content, should be taken into account while assessing the effects of honey on serum TG level to 
better elucidate the exact effects of honey on this parameter. Yet, the most important fact in the 
current meta-analysis was that the consumed fructose was in the form of honey, which had other 
ingredients that could modulate its final effects.  
As a natural food, honey can lead to protection against Metabolic Syndrome (MetS). It can 
prevent obesity and exert hypotensive, hypolipidemic, and anti-diabetic effects. It can affect 
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of honey that prevents fat accumulation in the body. However, the beneficial effects of honey 
have been poorly confirmed in diabetic patients and need to be further investigated in 
randomized clinical trials to better elucidate the exact effects 
(51)
. In spite of the hypoglycemic 
effects of natural honey, it was reported that it could possibly increase HbA1C in some diabetic 
patients 
(52)
. Considering the hypolipiodemic effects of honey, despite acceptable results, a 
previous review indicated that these effects were confirmed in some studies but not in some 
others 
(53)
. The effect of honey on blood lipids could be affected by different factors, including 
gender, type of honey, population, and geographical condition. Hence, further studies have to be 
conducted on the issue to draw a better conclusion. It is important to state that the results of the 
present study were not affected by any individual study according to the sensitivity analysis. 
Strengths of the study 
The results of the current meta-analysis pooled the available RCTs considering the effects of 
honey consumption on serum lipids. The study had some strengths. Firstly, there was a high 
heterogeneity among the studies. However, subgroup analysis was conducted considering the 
differences among the studies, including study duration, baseline serum lipid values, and their 
effects on changes in serum lipids after honey consumption, which was the main strength of the 
study. The large number of the studies included can be mentioned as another strong point. 
Limitations of the study 
This study had several limitations. Firstly, it was not registered in PROSPERO. In addition, a 
significant heterogeneity was encountered due to various regimens, doses, durations, center 
settings, and populations, and the results should be interpreted with caution. Besides, the studies 
could not be differentiated based on the utilization of natural or artificial honey, as it was not 
mentioned in all the included studies. In some studies, artificial or formulated honey was 
compared to natural honey, while many included studies explored the effects of honey compared 
to other sugar-containing foods and did not clearly define the type of honey consumed. Hence, 
differentiation of the studies based on the type of honey was not possible. Another limitation of 
the study was that the whole diet or dietary components of the study participants could not be 
investigated, as it was not reported in the included studies. As another limitation, most of the 
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Western countries. Finally, some studies suffered from some sources of bias, which should be 
considered while interpreting the results.  
Conclusions 
To sum up, the findings of this meta-analysis demonstrated that honey consumption had no 
effects on serum lipids, including TC, TG, HDL-C, LDL-C, LDL/HDL, and VLDL-C. However, 
to ensure the generalizability of the results, future studies with larger sample sizes, different 
populations, and various types of honey are required to clarify the effects of honey consumption 
on serum lipid profiles. In addition, the whole diet or dietary components have to be considered 
while assessing the effects of honey on serum lipid profiles in various populations. 
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CVDs: Cardiovascular Diseases; TC: Total Cholesterol; TG: Triglyceride; LDL-C: Low-Density 
Lipoprotein Cholesterol; HDL-C: High-Density Lipoprotein Cholesterol; VLDL-C: Very-Low-
Density Lipoprotein Cholesterol; BMI: Body Mass Index; SMD: Standardized Mean 
Differences; CIs: Confidence Intervals; SD: Standard Deviation; SE: Standard Error; CCRT: 
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TABLE 1. The characteristics of the clinical trials included in the meta-analysis of the effect of honey on lipid profiles 
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Table 3.b. Bias domains included in the ROBINS-I tool 
Study 
Bias domain Category of 
bias 
















Pre-intervention domains      
Bias due to 
confounding 
Confounding Moderate risk of 
bias 




into the study 
Selection bias No information No information No information No information 







No information No information No information No information 
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Confounding No information No information No information No information 
Bias due to 
missing data 














Moderate risk of 
bias 
Low risk of bias Moderate risk of bias Low risk of bias 
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Table 4. Summary of the findings 
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0.08) 
Serum TC 
     
 
Moderate 
0 0 +2 0 1   - 2   - RCT 
CT 
21 -0.0 (-0.23, 0.23) Serum TG 
     
 
Low 
0 -1 ¥ +2 0 1   - 2   - RCT 
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0 0 +2 0 1   - 2   - RCT 
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Very low 
 
0 0 -1 π 0 1   - 2   - RCT 
 




The symbols      show the quality of the evidence. 
 Abbreviations: WMD, weighted mean difference; CI, confidence interval; GRADE, grades of recommendation, assessment, development, and evaluation; RCT, 
randomized controlled trial; CT, controlled trial. 
€ Down-graded two levels as the serious risk of bias. 
£ Down-graded one level as the statistical heterogeneity was >50%. 
$ Up-graded two levels as the as the number of studies was >5 and imprecision was considerable. 
π Down-graded one level as the as the number of studies was <5 and imprecision was considerable. 
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Figure 2. Forest plot of the clinical trials examining the effect of honey on TC (mg/dL). Data have 
been expressed as SMDs between treatment and control groups with 95% CIs. Estimates were 
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Figure 3. Forest plot of the clinical trials examining the effect of honey on TG (mg/dL). Data have 
been expressed as SMDs between the treatment and control groups with 95% CIs. Estimates were 
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Figure 4. Forest plot of the clinical trials examining the effect of honey on LDL-C (mg/dL). Data 
have been expressed as SMDs between the treatment and control groups with 95% CIs. Estimates 
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Figure 5. Forest plot of the clinical trials examining the effect of honey on HDL-C (mg/dL). Data 
have been expressed as SMDs between the treatment and control groups with 95% CIs. Estimates 
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Figure 6. Forest plot of the clinical trials examining the effect of honey on LDL/HDL-C (mg/ dL). Data have 
been expressed as SMDs between the treatment and control groups with 95% CIs. Estimates were pooled using 
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Figure 7. Funnel plot for the identification of publication bias in the trials on TC, LDL-C, HDL-C, and LDL-
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